- Home
- CSTL vs NKX Comparison
CSTL vs NKX Comparison
Compare CSTL & NKX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- NKX
- Stock Information
- Founded
- CSTL 2007
- NKX 2002
- Country
- CSTL United States
- NKX United States
- Employees
- CSTL N/A
- NKX N/A
- Industry
- CSTL Medical Specialities
- NKX Finance/Investors Services
- Sector
- CSTL Health Care
- NKX Finance
- Exchange
- CSTL Nasdaq
- NKX Nasdaq
- Market Cap
- CSTL 561.9M
- NKX 562.3M
- IPO Year
- CSTL 2019
- NKX N/A
- Fundamental
- Price
- CSTL $16.53
- NKX $11.54
- Analyst Decision
- CSTL Strong Buy
- NKX
- Analyst Count
- CSTL 6
- NKX 0
- Target Price
- CSTL $37.67
- NKX N/A
- AVG Volume (30 Days)
- CSTL 396.8K
- NKX 109.3K
- Earning Date
- CSTL 08-04-2025
- NKX 01-01-0001
- Dividend Yield
- CSTL N/A
- NKX 4.37%
- EPS Growth
- CSTL N/A
- NKX N/A
- EPS
- CSTL N/A
- NKX N/A
- Revenue
- CSTL $347,083,000.00
- NKX N/A
- Revenue This Year
- CSTL N/A
- NKX N/A
- Revenue Next Year
- CSTL $1.36
- NKX N/A
- P/E Ratio
- CSTL N/A
- NKX N/A
- Revenue Growth
- CSTL 38.43
- NKX N/A
- 52 Week Low
- CSTL $15.45
- NKX $9.78
- 52 Week High
- CSTL $35.84
- NKX $12.00
- Technical
- Relative Strength Index (RSI)
- CSTL 34.83
- NKX 38.27
- Support Level
- CSTL $19.29
- NKX $11.70
- Resistance Level
- CSTL $20.26
- NKX $11.88
- Average True Range (ATR)
- CSTL 0.70
- NKX 0.07
- MACD
- CSTL -0.35
- NKX -0.01
- Stochastic Oscillator
- CSTL 4.44
- NKX 3.12
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About NKX Nuveen California AMT-Free Quality Municipal Income Fund
Nuveen California AMT-Free Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objectives are to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.